Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Urvi J. Patel, PharmD, MPH, and Sarah Caulfield, PharmD, BCOP
Emory University Hospital, Atlanta, Georgia; and Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia
Authors’ disclosures of conflicts of interest are found at the end of this article.
Urvi J. Patel, PharmD, MPH, Emory University Hospital, 1364 Clifton Road NE, B712, Atlanta, GA 30322.
J Adv Pract Oncol 2019;10(5):501–507 |
© 2019 Harborside™
Prostate cancer is the fourth leading cause of cancer in the United States. Treatment of this oncologic disease involves a variety of different modalities including surgery, radiation, and systemic therapy. Systemic therapy is used for locally advanced and metastatic disease, and primarily involves hormonal blockade as a mechanism of disease control. Apalutamide is a nonsteroidal androgen receptor inhibitor that binds directly to the androgen receptor ligand binding-domain to prevent androgen receptor translocation. This agent is used in combination with gonadotropin-releasing hormone antagonists to shut down the production of testosterone through the reproductive system. It is the first drug to receive U.S. Food & Drug Administration approval for the treatment of nonmetastatic, castration-resistant prostate cancer. This article reviews the pharmacology of apalutamide along with its current place in therapy and management of associated adverse events.
For access to the full length article, please sign in